Neuronetics Inc

Neuronetics, Inc. commercial stage medical technology company, which engages in the designing, developing and marketing products for the patients suffering from psychiatric disorders. It operates through United States and International geographical segments. The firm offers NeuroStar TMS, a therapy system for the treatment of major depressive disorders in adult patients. The company was founded by Steven B. Waite, Bruce J. Shook, Norman R. Weldon, and Thomas D. Weldon in April 2003 and is headquartered in Malvern, PA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Neuronetics reports robust Q4 performance, eyes nurse practitioner opportunities

Neuronetics delivered a strong performance in Q4 2022, showcasing revenue growth, operational achievements, and strategic partnerships.
While facing challenges in managing losses and revenue fluctuations, the company is focused on key initiatives and opportunities for future growth.
By leveraging upcoming opportunities with nurse practitioners and addressing analyst inquiries, Neuronetics aims to navigate challenges and drive sustainable growth in 2023.

Neuronetics Inc reports revenue growth and strategic advancements in Q1 2023

Neuronetics Inc's Q1 2023 performance reflects revenue growth, operational advancements, and strategic initiatives aimed at driving market expansion and financial stability.
While facing challenges in gross margin decline and negative EBITDA, the company's focus on cost management, recovery from merger disruption, and revenue guidance raise position it for future success.
With opportunities in expanded patient access, market growth, and product enhancements, Neuronetics is poised to capitalize on its strengths and navigate challenges effectively in the coming quarters.

Neuronetics reports solid Q2 performance, eyes growth amidst challenges

Neuronetics demonstrated resilience and growth in Q2 2023, with revenue increases and strategic advancements in technology and policy.
While facing challenges from closures and relocations, the company remains focused on financial stability and operational efficiency.
Opportunities lie in new technology clearances, favorable policy changes, and the growing demand for TMS therapy education and services.
Overall, Neuronetics' performance, strengths, challenges, and opportunities position the company for continued growth and market impact.

Neuronetics Inc reports solid Q3 earnings, faces challenges in expenses

Neuronetics Inc (STIM) delivered a strong performance in Q3 2023, showcasing revenue growth and operational advancements.
While facing challenges in aligning revenue with operating expenses, the company maintains a solid financial position and pursues growth opportunities.
By focusing on enhancing patient care standards, expanding market reach, and optimizing financial performance, Neuronetics Inc aims to drive sustainable growth and value creation.

Neuronetics Inc posts record revenue in Q4 2023 earnings call

Neuronetics Inc delivered a strong Q4 performance with revenue growth and achieving positive cash flow for the first time. The company's focus on strategic initiatives, regulatory advancements, and revenue guidance for 2024 indicate a positive trajectory for growth and profitability.

Neuronetics Inc reports revenue growth and strategic partnerships in Q1

Neuronetics Inc's Q1 2024 performance reflects revenue growth, operational efficiency improvements, and a strong financial position.
Strengths include successful programs, strategic partnerships, and growth opportunities in new market segments.
Challenges in system sales and revenue collection highlight areas for improvement, while opportunities in market expansion and revenue growth are promising.
Overall, Neuronetics shows resilience, innovation, and a strategic focus on driving growth and improving patient outcomes.

Neuronetics Inc reports Q2 revenue decline, eyes growth opportunities

Neuronetics Inc faced revenue challenges due to a cybersecurity breach but showed resilience in key areas.
Strategic adjustments and positive program results indicate a focus on growth and market expansion.
Acquisition and new debt facility offer opportunities for future expansion and financial stability.

Neuronetics reports solid Q3 earnings, eyes profitability and growth

Neuronetics is focused on optimizing operations, profitability, and cash flow breakeven by Q3 2025.
Greenbrook acquisition approval and strong business position provide a foundation for future growth.
Challenges include managing treatment session weakness and debt levels while pursuing revenue growth opportunities.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Neuronetics, Inc. is a commercial stage medical technology company, which focuses on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders. It operates through United States and International geographical segments. The company was founded by Steven B. Waite, Bruce J. Shook, Norman R. Weldon, and Thomas D. Weldon in 1998 and is headquartered in Malvern, PA.

MALVERN, Pa., July 28, 2022 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial-stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurological health disorders, today announced that Keith Sullivan, President and Chief Executive Officer, and Steve Furlong, Senior Vice President, Chief Financial Officer, and Treasurer will present at the Canaccord Genuity 42nd Annual Growth Conference on Thursday, August 11, 2022. The Company is scheduled to present at 11:30 am Eastern Time the same day via webcast.

Neuronetics to Present at the Canaccord Genuity 42nd Annual Growth Conference

Partnership Will Bring Non-drug NeuroStar® Advanced Therapy for Mental Health to Thousands More Patients

Neuronetics and Alleviant Health Centers Announce Exclusive Partnership

Neuronetics (STIM) stock is taking off on Tuesday after the announcing approval from the FDA for a new use of a metal health treatment. The post Why Is Neuronetics (STIM) Stock Up 12% Today?

Why Is Neuronetics (STIM) Stock Up 12% Today?

Shares of Neuronetics Inc. STIM, -6.67% gained 22.5% in premarket trading on Tuesday after the company said it received clearance from the Food and Drug Administration to market its transcranial magnetic stimulation system as a treatment for anxiety in adults with major depressive disorder. The system was previously cleared to treat obsessive-compulsive disorder.

Neuronetics gets another FDA clearance for transcranial magnetic stimulation system; shares jump 22%

MALVERN, Pa., July 19, 2022 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, today announced that it plans to release second quarter 2022 financial and operating results prior to market open on Tuesday, August 2nd, 2022. The Company will host a conference call to review its results at 8:30 a.m. Eastern Time the same day.

Neuronetics to Report Second Quarter 2022 Financial and Operating Results and Host Conference Call

The FDA has cleared Neuronetics Inc's (NASDAQ: STIM) NeuroStar Advanced Therapy for Mental Health – to treat anxiety symptoms for adult patients with major depressive disorder (MDD), also known as anxious depression. NeuroStar is a patient-focused Transcranial magnetic.

Read Why Neuronetics Shares Are Trading Higher Today

Indication demonstrates NeuroStar TMS safety and efficacy in improving anxiety symptoms in depressed patients Indication demonstrates NeuroStar TMS safety and efficacy in improving anxiety symptoms in depressed patients

NeuroStar® Advanced Therapy for Mental Health Receives FDA Clearance for Treatment of Anxious Depression

Technology is awarded for its innovation to treat depression with NeuroStar Advanced Therapy for Mental Health Technology is awarded for its innovation to treat depression with NeuroStar Advanced Therapy for Mental Health

Neuronetics Recognized as Top Non-Invasive Devices Provider in 2022

Proposed Medicare Coverage through First Coast and Novitas MACs Will Reduce Number of Medication Trials for TMS Eligibility Proposed Medicare Coverage through First Coast and Novitas MACs Will Reduce Number of Medication Trials for TMS Eligibility

Neuronetics Announces Positive TMS Coverage Policies to Expand Patient Access to NeuroStar TMS Therapy for Mental Health

MALVERN, Pa., May 25, 2022 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial-stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurological health disorders, today announced that Keith Sullivan, President and Chief Executive Officer, and Steve Furlong, Senior Vice President, Chief Financial Officer, and Treasurer will present at the William Blair 42nd Annual Growth Stock Conference. The Company is scheduled to present on Wednesday, June 8, 2022 at 2:20pm ET.

Neuronetics to Present at the William Blair 42nd Annual Growth Stock Conference

Published in Brain Stimulation Journal, study describes insights from world's largest depression registry

New Peer-Reviewed Data Continue to Further Best Practices with NeuroStar® Advanced Therapy

Neuronetics, Inc. (NASDAQ:STIM ) Q1 2022 Earnings Conference Call May 12, 2022 8:30 AM ET Company Participants Mark Klausner – Investor Relations Keith Sullivan – President and Chief Executive Officer Steve Furlong – Senior Vice President, Chief Financial Officer and Treasurer Conference Call Participants Adam Maeder – Piper Sandler Bill Plovanic – Canaccord Marie Thibault – BTIG Operator Good day, and thank you for standing by. Welcome to the Neuronetics First Quarter 2022 Financial and Operating Results Conference Call.

Neuronetics' (STIM) CEO Keith Sullivan on Q1 2022 Results - Earnings Call Transcript

MALVERN, Pa., May 12, 2022 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company with a strategic vision of transforming the lives of patients whenever and wherever they need it with the best neurohealth therapies in the world, today announced its financial and operating results for the first quarter of 2022.

Neuronetics Reports First Quarter 2022 Financial and Operating Results

MALVERN, Pa., May 11, 2022 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company with a strategic vision of transforming the lives of patients whenever and wherever they need it with the best neurohealth therapies in the world, today announced an extended commercial partnership with Transformations Care Network (“Transformations”), one of the nation's largest mental healthcare providers. Under the agreement, the Transformations Care Network will continue to expand upon its multi-state footprint of NeuroStar systems.

Neuronetics and Transformations Care Network Announce Extended Commercial Partnership

NeuroStar data from largest depression outcomes registry in the world to be highlighted NeuroStar data from largest depression outcomes registry in the world to be highlighted

Neuronetics TMS Leadership on Display at Clinical TMS Society Annual Meeting

MALVERN, Pa., May 11, 2022 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, today announced the filing of a federal lawsuit in the District of Delaware against Brainsway Ltd. and Brainsway USA Inc. for unfair competition under the Lanham Act and state law.

Neuronetics Files Federal Lawsuit Against Brainsway for Misleading Psychiatrists and Patients

Clearance allows for more access to non-drug, noninvasive treatment for patients suffering from MDD or OCD Clearance allows for more access to non-drug, noninvasive treatment for patients suffering from MDD or OCD

NeuroStar® Advanced Therapy for Mental Health Receives FDA Clearance for Treatment of Obsessive-Compulsive Disorder

Symbolic Logic, Inc.

Movano

The ISM services PMI rose to 58.3 in March from 56.5 in the previous month. Investors, meanwhile, focused on some notable insider trades.

Executives Buy Around $1M Of 4 Penny Stocks

Neuronetics Inc (NASDAQ: STIM) reported Q4 FY21 sales of $15.02 million, down 4% Y/Y, exceeding previously issued guidance of $13.0 million - $14.0 million and the consensus of $14.43 million. U.S. revenue decreased by 3% during the quarter, and international revenue decreased by 13% Y/Y.

Neuronetics Posts Better Than Expected Q4 Results Despite Lower NeuroStar Therapy System Sales

Neuronetics, Inc. (STIM) CEO Keith Sullivan on Q4 2021 Earnings Call Transcript

MALVERN, Pa., March 08, 2022 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company with a strategic vision of transforming the lives of patients whenever and wherever they need it with the best neurohealth therapies in the world, today announced its financial and operating results for the fourth quarter and full year of 2021.

Neuronetics Reports Fourth Quarter and Full Year 2021 Financial and Operating Results

Company invests $14.5 million to expand education for patients and physicians about NeuroStar® Advanced Therapy Company invests $14.5 million to expand education for patients and physicians about NeuroStar® Advanced Therapy

NeuroStar® Advanced Therapy Launches New “Tap Into a New Possibility” Campaign for Depression Awareness

New Technology provides 40% time-savings for practices and patients New Technology provides 40% time-savings for practices and patients

MT Cap for NeuroStar Advanced Therapy for Mental Health Now Available Nationwide

MALVERN, Pa., Feb. 22, 2022 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, today announced that it plans to release fourth quarter and fiscal year 2021 financial and operating results prior to market open on Tuesday, March 8, 2022. The Company will host a conference call to review its results at 8:30 a.m. Eastern Time the same day.

Neuronetics to Report Fourth Quarter and Fiscal Year 2021 Financial and Operating Results and Host Conference Call

MALVERN, Pa., Feb. 22, 2022 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, today announced it has amended its term loan agreement with its current lenders, investment affiliates managed by SLR Investment Corp. (SLR), which was originally entered into on March 2, 2020 and subsequently amended on April 20, 2020 and December 2, 2020. This amendment includes modifications to the ability of the Company to extend the interest-only period, the reduction of certain revenue covenants, and the elimination of the final term loan tranche available to the Company.

News for Neuronetics Inc Stock (STIM)